Search results
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga via AOL· 12 hours agoBristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer...
BMS’ Opdivo-Yervoy treatment improves survival in hepatocellular carcinoma trial
Clinical Trials Arena via Yahoo Finance· 2 days agoBristol Myers Squibb (BMS) has announced findings from the Phase III CheckMate -9DW trial where ...
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients -...
Benzinga· 3 days agoOpdivo plus Yervoy combo shows significant survival benefits and higher response rates vs....
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 3 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
MedPage Today· 3 days agoCombination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical...
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
Pharmaceutical Technology via Yahoo Finance· 22 hours agoIn May 2024 the European Commission approved BMS's Opdivo (nivolumab) combination with gemcitabine...
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers
MedPage Today· 3 days agoAmong 14 patients who received nivolumab alone, there were two partial responses and no complete...
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 4 days agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
Replimune up 30% on results for RP1 combo in melanoma (NASDAQ:REPL)
Seeking Alpha· 15 hours agoReplimmune Group reports positive results in melanoma patients who failed on PD-1 inhibitors,...
Perioperative Chemo Extends Survival in Resectable Esophageal Cancer
MedPage Today· 4 days agoA perioperative regimen of four cycles of chemotherapy before and after surgery extended overall...